Rocket Pharma gains on trial update for gene therapy

spawns Rocket Pharmaceuticals ( NASDAQ: RCKT ) traded higher on Tuesday after the company announced that all patients are enrolled in its pivotal Phase 2 trial for its gene therapy candidate RP-A501, which targets Danon disease, a rare cardiovascular condition. The global single-arm study.